Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives $139.80 Average Price Target from Brokerages

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) have been given an average recommendation of “Moderate Buy” by the fifteen ratings firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, thirteen have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $139.80.

Several equities research analysts recently commented on MIRM shares. Wolfe Research initiated coverage on Mirum Pharmaceuticals in a report on Tuesday, May 19th. They issued an “outperform” rating and a $145.00 price objective for the company. Citigroup restated an “outperform” rating on shares of Mirum Pharmaceuticals in a research note on Monday, June 15th. TD Cowen lifted their price target on shares of Mirum Pharmaceuticals from $125.00 to $145.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Stifel Nicolaus set a $136.00 price objective on shares of Mirum Pharmaceuticals in a report on Thursday, May 7th. Finally, Wall Street Zen downgraded shares of Mirum Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th.

Insider Activity

In other news, SVP Jolanda Howe sold 2,594 shares of the firm’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $101.95, for a total value of $264,458.30. Following the transaction, the senior vice president directly owned 5,835 shares in the company, valued at $594,878.25. This trade represents a 30.77% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Eric Bjerkholt sold 5,000 shares of the stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $93.82, for a total value of $469,100.00. Following the completion of the transaction, the chief financial officer directly owned 44,788 shares in the company, valued at approximately $4,202,010.16. This represents a 10.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 37,594 shares of company stock valued at $3,608,758 in the last ninety days. 8.32% of the stock is currently owned by company insiders.

Institutional Trading of Mirum Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. Faithward Advisors LLC raised its position in Mirum Pharmaceuticals by 0.5% in the first quarter. Faithward Advisors LLC now owns 27,467 shares of the company’s stock worth $2,537,000 after acquiring an additional 126 shares during the period. Janney Montgomery Scott LLC boosted its stake in shares of Mirum Pharmaceuticals by 6.7% during the 4th quarter. Janney Montgomery Scott LLC now owns 3,200 shares of the company’s stock worth $253,000 after acquiring an additional 200 shares during the last quarter. Jones Financial Companies Lllp grew its position in shares of Mirum Pharmaceuticals by 34.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 957 shares of the company’s stock valued at $70,000 after acquiring an additional 243 shares during the period. Comerica Bank grew its position in shares of Mirum Pharmaceuticals by 45.1% during the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after acquiring an additional 278 shares during the period. Finally, Osaic Holdings Inc. increased its stake in shares of Mirum Pharmaceuticals by 46.5% in the 2nd quarter. Osaic Holdings Inc. now owns 1,106 shares of the company’s stock worth $56,000 after purchasing an additional 351 shares in the last quarter.

Mirum Pharmaceuticals Price Performance

Shares of MIRM opened at $107.77 on Thursday. Mirum Pharmaceuticals has a twelve month low of $47.89 and a twelve month high of $114.99. The company has a market capitalization of $6.57 billion, a P/E ratio of -7.92 and a beta of 0.50. The firm has a 50 day moving average of $98.87 and a 200 day moving average of $92.64. The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 1.28.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Wednesday, May 6th. The company reported ($13.43) EPS for the quarter, missing the consensus estimate of ($0.75) by ($12.68). Mirum Pharmaceuticals had a negative net margin of 140.24% and a negative return on equity of 11.28%. The business had revenue of $159.88 million for the quarter, compared to analysts’ expectations of $148.21 million. During the same quarter in the prior year, the business posted ($0.30) earnings per share. The business’s revenue for the quarter was up 43.3% on a year-over-year basis. As a group, equities research analysts anticipate that Mirum Pharmaceuticals will post -2.01 earnings per share for the current fiscal year.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.